fda glp-1 compounding warning october 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns – Partnership for Safe Medicines How GLP-1s Broke Healthcare Distribution

Common gastrointestinal effects reported with GLP-1 therapy include: Nausea (commonly reported, especially during dose escalation) Constipation or diarrhoea Abdominal discomfort or bloating Reduced appetite and early satiety Regarding bowel movement colour specifically, changes in stool colour are not listed as adverse effects in UK SmPCs for GLP-1 receptor agonists

Manufacturer's country: USA

6 facts about obesity and GLP-1 weight loss drugs in the US. pewresearch.org 7KFF (January 2026)

But what Ive discovered is that it is not a copout

The risk appears to be rare, and the evidence is not fully settled

Sources Barakat GM et al